{"result": {"id": "6f56d52b-9cd9-4e64-a3eb-e294f94bcb13", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CARBONATE CALCIUM<|>ORGANIZATION<|>A medication used in the treatment of osteoporosis/osteoarthritis/gout, which can interact with other drugs like levofloxacin, reducing its efficacy by lowering its AUC and Cmax>  \n##  \n(\"entity\"<|>LEVOFLOXACIN<|>ORGANIZATION<|>An antibiotic whose efficacy can be reduced when co-administered with calcium carbonate, particularly in cystic fibrosis patients>  \n##  \n(\"entity\"<|>COLCHICINE<|>ORGANIZATION<|>A medication for gout that can cause severe toxicity like rhabdomyolysis and renal failure when combined with clarithromycin due to increased AUC from CYP3A4 and P-gp inhibition>  \n##  \n(\"entity\"<|>CLARITHROMYCIN<|>ORGANIZATION<|>An antibiotic that inhibits CYP3A4 and P-gp, increasing colchicine's AUC and leading to severe toxicity>  \n##  \n(\"entity\"<|>ALLOPURINOL<|>ORGANIZATION<|>A drug for gout that inhibits xanthine oxidase, slowing azathioprine metabolism and increasing its active metabolite levels, leading to bone marrow suppression>  \n##  \n(\"entity\"<|>AZATHIOPRINE<|>ORGANIZATION<|>An immunosuppressant whose metabolism is slowed by allopurinol, increasing the risk of bone marrow suppression>  \n##  \n(\"entity\"<|>CEFTRIAXONE<|>ORGANIZATION<|>An antibiotic that can cause disulfiram-like reactions when combined with ethanol>  \n##  \n(\"entity\"<|>ERYTHROMYCIN<|>ORGANIZATION<|>An antibiotic that inhibits CYP3A4, prolonging QTc interval when combined with cisapride, leading to arrhythmias>  \n##  \n(\"entity\"<|>CISAPRIDE<|>ORGANIZATION<|>A gastrointestinal motility agent whose metabolism is slowed by erythromycin, increasing the risk of QTc prolongation and arrhythmias>  \n##  \n(\"entity\"<|>CIPROFLOXACIN<|>ORGANIZATION<|>An antibiotic that inhibits CYP1A2, increasing theophylline's AUC and risk of toxicity>  \n##  \n(\"entity\"<|>THEOPHYLLINE<|>ORGANIZATION<|>A bronchodilator whose metabolism is inhibited by ciprofloxacin, leading to increased AUC and toxicity risk>  \n##  \n(\"entity\"<|>LINEZOLID<|>ORGANIZATION<|>An antibiotic that inhibits MAO, increasing the risk of serotonin syndrome when combined with fluoxetine>  \n##  \n(\"entity\"<|>FLUOXETINE<|>ORGANIZATION<|>An SSRI that can cause serotonin syndrome when combined with linezolid due to synergistic effects on serotonin metabolism>  \n##  \n(\"entity\"<|>ITRACONAZOLE<|>ORGANIZATION<|>An antifungal that significantly increases felodipine's Cmax and AUC, leading to hypotension>  \n##  \n(\"entity\"<|>FELODIPINE<|>ORGANIZATION<|>A calcium channel blocker whose levels are drastically increased by itraconazole, raising the risk of hypotension>  \n##  \n(\"relationship\"<|>CARBONATE CALCIUM<|>LEVOFLOXACIN<|>Calcium carbonate reduces levofloxacin's efficacy by lowering its AUC and Cmax<|>7>  \n##  \n(\"relationship\"<|>COLCHICINE<|>CLARITHROMYCIN<|>Clarithromycin increases colchicine's AUC by inhibiting CYP3A4 and P-gp, leading to severe toxicity<|>8>  \n##  \n(\"relationship\"<|>ALLOPURINOL<|>AZATHIOPRINE<|>Allopurinol slows azathioprine metabolism, increasing its active metabolite levels and risk of bone marrow suppression<|>7>  \n##  \n(\"relationship\"<|>CEFTRIAXONE<|>ERYTHROMYCIN<|>Erythromycin inhibits CYP3A4, increasing cisapride's QTc prolongation effect when co-administered<|>6>  \n##  \n(\"relationship\"<|>CIPROFLOXACIN<|>THEOPHYLLINE<|>Ciprofloxacin inhibits theophylline metabolism via CYP1A2, increasing its AUC and toxicity risk<|>7>  \n##  \n(\"relationship\"<|>LINEZOLID<|>FLUOXETINE<|>Linezolid and fluoxetine synergistically increase serotonin levels, raising the risk of serotonin syndrome<|>8>  \n##  \n(\"relationship\"<|>ITRACONAZOLE<|>FELODIPINE<|>Itraconazole drastically increases felodipine's Cmax and AUC, leading to hypotension<|>9>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166534, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1089, "prompt_tokens": 2472, "total_tokens": 3561, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 680}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 相关药物相互作用的潜在危害及 处置见表 11。\n4.12    常用 OTC 药物、天然药物、保健品、饮料  天然 药物（包括中药） 中的某些成分具有确定的CYP450 酶\n\n表 9    治疗骨质疏松 / 骨关节炎 / 痛风药相关药物相互作用的潜在危害及处置\nTable 9     Potential risk and management of drug interactions in the treatment of osteoporosis/osteoarthritis/gout\n\n药物名称\t联合药物\t临床后果\t药动学改变\t相互作用机制\t临床建议\n碳酸钙\t左氧氟沙星\t降低疗效\t对于囊性纤维化患者，合用碳酸钙使左 氧氟沙星的 Cmax  降低 19%，tmax 延长 37%\t碳酸钙可降低左氧氟沙星的 AUC\t谨慎合用\n秋水仙碱\t克拉霉素\t横纹肌溶解症、 肾衰竭、急性  神经肌病\t合用克拉霉素使秋水仙碱 AUC0 → infinity 增 加 125%\t秋水仙碱是 P-gp 的底物，克拉霉素抑制 CYP3A4 和 P-gp，增加秋水仙碱 AUC，减 慢其代谢，导致严重毒性\t谨慎合用\n别嘌醇\t硫唑嘌呤\t骨髓抑制\t别嘌醇抑制黄嘌呤氧化酶而升高硫唑嘌 呤的活性代谢物巯嘌呤的血药浓度\t别嘌醇抑制黄嘌呤氧化酶，显著减慢了硫 唑嘌呤的代谢\t谨慎合用\n\n表 10    抗感染药相关药物相互作用的潜在危害及处置\nTable 10     Potential risk and management of drug interactions in the treatment of infection\n\n药物名称\t联合药物\t临床后果\t药物动力学改变\t相互作用机制\t临床建议\n头孢曲松 红霉素\t乙醇\n西沙必利\t双硫仑样反应\n尖端扭转型室性心 动过速\t参见说明书\n合用西沙必利和红霉素后导致患者 QTc 延长而出现心律失常\t不详\n　红霉素抑制 CYP3A4，减慢西沙必利代谢， 增强其对心脏 QTc 延长的作用。红霉素本身\t避免合用 避免合用\n环丙沙星\t茶碱\t茶碱中毒\t　合用环丙沙星使茶碱 AUC 增加 45% （15%~77%）\t也有延长 QTc 的作用\n环丙沙星抑制茶碱经 CYP1A2 的代谢\t谨慎合用\n利奈唑胺\t氟西汀\t5- 羟色胺综合征\t参见说明书\t　利奈唑胺抑制 MAO 减慢内源性的 5- 羟色胺 代谢，与氟西汀产生药效学的协同或相加作 用，也会导致 5- 羟色胺综合征发生\t避免合用\n伊曲康唑\t非洛地平\t导致低血压\t合用伊曲康唑使非洛地平的 Cmax 升高 近 8 倍，AUC0 → infinity 增加近 6 倍，t1/2 延长近 2 倍\t伊曲康唑\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_c2f76f821babf9cdb59673c47475b35277a9ef50b86bcd9314528f40f42e260c_v2"}